1-(|A-D-Xylofuranosyl)uracil

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-(|A-D-Xylofuranosyl)uracil
• 英文别名: 1-[(2R,3S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
• 化学式: C₉H₁₂N₂O₆
• 分子量: 244.204
• InChiKey: DRTQHJPVMGBUCF-PDVZPSIWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  119
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF<br/>[FR] MOLÉCULES D'ACIDE NUCLÉIQUE MODIFIÉES ET LEURS UTILISATIONS
  申请人：MODERNA THERAPEUTICS INC

  公开号：WO2014093924A1

  公开（公告）日：2014-06-19

  The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.

  本公开提供了经修改的核苷、核苷酸和核酸，以及它们的使用方法。
• METHOD FOR THE SYNTHESIS OF CLOFARABINE
  申请人：SYNBIAS PHARMA AG

  公开号：US20170044204A1

  公开（公告）日：2017-02-16

  The present invention relates to a method for the high yield production of the anticancer nucleoside clofarabine, the method comprising the preparation of 2-chloroadenosine by enzymatic transglycosylation between 2-chloroadenine and nucleosides, benzoylation, isomerization, sulfonate ester formation, fluorination, and deprotection.

  本发明涉及一种高产抗癌核苷类药物克洛法滨的生产方法，该方法包括通过酶促转糖基反应在2-氯腺苷和核苷类化合物之间制备2-氯腺苷，然后进行苯甲酰化、异构化、磺酸酯形成、氟化和去保护等步骤。
• Hydrophobically Modified Antisense Oligonucleotides Comprising a Ketal Group
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：US20160108398A1

  公开（公告）日：2016-04-21

  The present invention concerns an oligonucleotide modified by substitution at the 3′ or the 5′ end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.

  本发明涉及一种寡核苷酸，其在3′或5′端被含有至少一个缩醛官能团的基团取代，其中所述缩醛官能团的缩醛碳带有两个饱和或不饱和、线性或支链、碳原子数为1至22的烃链，并且用作药物，特别用于治疗癌症。
• CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION
  申请人：Manoharan Muthiah

  公开号：US20120035115A1

  公开（公告）日：2012-02-09

  The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.

  该发明涉及公式I或II的化合物：在一种实施方式中，该发明涉及化合物和用于将配体与寡核苷酸结合的过程。该发明进一步涉及治疗各种疾病和疾病的方法，例如病毒感染、细菌感染、寄生虫感染、癌症、过敏、自身免疫疾病、免疫缺陷和免疫抑制。
• URIDINE MONOPHOSPHATE AND TRIPHOSPHATE DERIVATIVES, COMPOSITIONS AND METHODS OF USE
  申请人：Tufts University

  公开号：US20180085386A1

  公开（公告）日：2018-03-29

  This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to compounds, such as agonists, of P 2 Y 6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.

  该披露涉及尿苷核苷衍生物，包括含有这些核苷衍生物的治疗有效量的组合物，以及使用这些核苷衍生物或组合物治疗对P2Y6受体的化合物（如激动剂）具有响应的疾病的方法，例如神经元疾病，包括神经退行性疾病（如阿尔茨海默病、帕金森病）和创伤性中枢神经系统损伤、疼痛、唐氏综合征（DS）、青光眼和炎症性疾病。